The University of Chicago Biotechnology Association's leaders describe the events and career advancement tools that their club offers to those interested in biotech
Gene therapy experts TJ Cradick and Andrew Kernytsky discuss the issues surrounding unintended off-target editing of genetic tools like CRISPR
The Foundation for Innovation and Tech Transfer has consolidated business development and tech transfer for 7 institutions in northern Italy to expedite the commercialization of the area's research
Lundbeck CEO Charl van Zyl describes the rationale for today's $2.6 billion acquisition of Longboard Pharma
Ghent based Confo Therapeutics is leveraging GPCR expertise as a discovery engine - multiple partners have already signed on to the science
Copenhagen based FluoGuide is working to light up tumors for surgeons by guiding fluorescent molecules to uPAR - a target that has been studied widely in Scandinavia
IO Biotech is developing a cancer vaccine that targets both the tumor and its microenvironment - a pivotal readout is coming in the first half of next year
The co-founder of the startup Ousia Pharma describes working from Copenhagen's BioInnovation Institute on his company's next-generation enhancer to GLPs
The BioInnovation Institute in Copenhagen was founded by the Novo Nordisk Foundation to help turn local ideas in life sciences into commercial enterprises
A deep-dive discussion on obesity drug development with Zealand Pharma's CEO Adam Steensberg
Biotech veteran Hans Schikan gives an overview of the Netherlands' life sciences scene
Ronald Plasterk introduces us to his new company, Tzu Cancer Therapeutics, and the importance of focusing on circulating tumor cells
Leyden Labs is developing antibody-based nasal sprays that aim to stop viruses like flu and covid at the mucosa and with broad protection
Edinburgh HQ'd Resolution Therapeutics announced a £63.5M series B this month to advance its pro-regenerative macrophage therapy into further end-stage liver disease studies
Leiden based ProQR invented the idea of using RNA oligonucleotides to induce ADAR to edit RNA over 10 years ago - the first programs are scheduled to enter the clinic soon
George Church on founder led companies, synthetic biology technologies, the future, and more
BioVenture VoiCes Episode 3: Time BioVentures' D.A. Wallach
Oxford, UK based Enara Bio announced a $32.5M series B to further its work developing TCR based therapies that target antigens found in the 'dark genome'
Mizuho senior analyst Graig Suvannavejh joins BiotechTV for Analyst Thursdays from Kendall Square
Gene therapy experts TJ Cradick and Kate Excoffon discuss using AAV gene therapy for cystic fibrosis
.png){kind=logo}
